Qilu Hospital of Shandong University, Jinan, Shandong Province, China.
Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province, China.
Medicine (Baltimore). 2023 Nov 3;102(44):e35509. doi: 10.1097/MD.0000000000035509.
Sodium tanshinone IIA sulfonate injection (STS) is widely used in the clinical treatment of coronary heart disease angina pectoris (CHDAP). This article systematically summarizes and evaluates the available evidence for STS in the treatment of AP, and assess its quality.
Two researchers searched and extracted 8 databases for systematic reviews (SRs)/meta-analyses (MAs), and independently assessed the methodological quality, risk of bias, reporting quality, and quality of evidence of SRs/MAs included in randomized controlled trials (RCTs). Tools used included the Assessment of Multiple Systematic Reviews 2 (AMSTAR-2), the risk of bias in systematic (ROBIS) scale, the list of Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA), and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system.
This overview includes 11 SRs/MAs that use quantitative calculations to comprehensively evaluate various efficacies of STS in AP intervention. The methodological quality, reporting quality, risk of bias, and quality of evidence for outcome measures of SRs/MAs were all unsatisfactory. All SRs/MAs are of low quality according to the results of the AMSTAR-2 assessment, and only a small number of SRs/MAs were assessed as low risk of bias based on the results of the ROBIS assessment, and none of the SRs/MAs has been fully reported on the checklist. According to GRADE system, 33 outcomes were extracted from the included SRs/MAs for evaluation, of which 12 were rated as moderate-quality evidence, 7 as low-quality evidence, and 14 as very low-quality evidence. Limitations included the lack of essential items such as protocol registration, screening of duplicate studies, provision of a list of excluded studies and assessment of publication bias.
Tanshinone IIA Sulfonate Sodium Injection may be an effective and safe treatment method. However, further standardized, comprehensive SRs/MAs and RCTs are needed to provide evidence-based medical support.
丹参酮ⅡA 磺酸钠注射液（STS）广泛用于冠心病心绞痛（CHDAP）的临床治疗。本文系统地总结和评估了 STS 治疗 AP 的现有证据，并评估其质量。
两名研究人员搜索并提取了 8 个数据库中的系统评价（SR）/荟萃分析（MA），并独立评估了包含在随机对照试验（RCT）中的 SR/MA 的方法学质量、偏倚风险、报告质量和证据质量。使用的工具包括 AMSTAR-2 评估、系统偏倚风险（ROBIS）量表、系统评价和荟萃分析报告的首选条目清单（PRISMA）和推荐评估、制定和评估分级（GRADE）系统。
该综述包括 11 项使用定量计算全面评估 STS 在 AP 干预中的各种疗效的 SR/MA。SR/MA 的方法学质量、报告质量、偏倚风险和结局指标的证据质量均不理想。根据 AMSTAR-2 评估结果，所有 SR/MA 均为低质量，根据 ROBIS 评估结果，仅有少数 SR/MA 被评估为低偏倚风险，并且没有一项 SR/MA 对清单进行了全面报告。根据 GRADE 系统，从纳入的 SR/MA 中提取了 33 个结局进行评估，其中 12 个被评为中等质量证据，7 个为低质量证据，14 个为极低质量证据。局限性包括缺乏必要的项目，如方案注册、重复研究的筛选、排除研究的清单以及发表偏倚的评估。
丹参酮ⅡA 磺酸钠注射液可能是一种有效且安全的治疗方法。然而，需要进一步的标准化、全面的 SR/MA 和 RCT 来提供基于证据的医学支持。
